How we mobilize haemopoietic stem cells

Internal Medicine Journal

Volumn 41, Issue 8, 2011, Pages 588-594

  Herbert, K E ^a   Levesque, J P ^c,d   Mills, A K ^e   Gottlieb, D J ^f   Cooney, J ⁱ   Szer, J ^b   Rasko, J ^g,h   To, L Bik ^j  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c MATER MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e Princess Alexandra Hospital   (United States)

^f UNIVERSITY OF SYDNEY   (Australia)

^g Centenary Institute   (United States)

^h ROYAL PRINCE ALFRED HOSPITAL   (Australia)

ⁱ ROYAL PERTH HOSPITAL   (Australia)

^j UNIVERSITY OF ADELAIDE   (Australia)

more..

Author keywords

G CSF; Haemopoietic stem and progenitor cell; Plerixafor; Stem cell factor; Stem cell mobilization

Indexed keywords

CYCLOPHOSPHAMIDE; PLERIXAFOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT STEM CELL FACTOR;

ALGORITHM; ALKALINE PHOSPHATASE BLOOD LEVEL; APHERESIS; ARTHRALGIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE PAIN; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG USE; FATIGUE; FEVER; HEADACHE; HEMATOPOIETIC STEM CELL; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; LYMPHOMA; MYELOMA; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; VOMITING;

EID: 80051596538     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2011.02544.x     Document Type: Article

References (29)

1. Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G etal. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010; 45: 219-34.
2. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood 1997; 89: 2233-58.
3. Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D etal. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-4.
4. Visani G, Lemoli R, Tosi P, Martinelli G, Testoni N, Ricci P etal. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells. Bone Marrow Transplant 1999; 24: 467-72.
5. Gertz MA. Current status of stem cell mobilization. Br J Haematol 2010; 150: 647-62.
6. Uy GL, Rettig MP, Cashen AF. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. Expert Opin Biol Ther 2008; 8: 1797-804.
7. Levesque JP, Helwani FM, Winkler IG. The endosteal 'osteoblastic' niche and its role in hematopoietic stem cell homing and mobilization. Leukemia 2010; 24: 1979-92.
8. Greenbaum AM, Link DC. Mechanisms of G-CSF-mediated hematopoietic stem and progenitor mobilization. Leukemia 2011; 25: 211-17.
9. Winkler IG, Sims NA, Pettit AR, Barbier V, Nowlan B, Helwani F etal. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood 2010; 116: 4815-28.
10. Christopher MJ, Rao M, Liu F, Woloszynek JR, Link DC. Expression of the G-CSF receptor in monocytic cells is sufficient to mediate hematopoietic progenitor mobilization by G-CSF in mice. J Exp Med 2011; 208: 251-60.
11. Chow A, Lucas D, Hidalgo A, Mendez-Ferrer S, Hashimoto D, Scheiermann C etal. Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J Exp Med 2011; 208: 261-71.
12. Halter J, Kodera Y, Ispizua AU, Greinix HT, Schmitz N, Favre G etal. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica 2009; 94: 94-101.
13. DiPersio J, Stadtmauer EA, Nademanee AP, Stiff P, Micallef I, Angell J etal. A phase III, multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (plerixafor)+G-CSF vs. G-CSF+placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation. ASH Annual Meeting Abstracts. Blood 2007; 110: 445.
14. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E etal. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767-73.
15. Flomenberg N, Devine SM, DiPersio JF, Liesveld JL, McCarty JM, Rowley SD etal. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867-74. 10.1182/blood-2005-02-0468.
16. Jantunen E, Fruehauf S. Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens. Bone Marrow Transplant 2011; 46: 627-35.
17. Costa LJ, Miller AN, Alexander ET, Hogan KR, Shabbir M, Schaub C etal. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transplant 2011; 46: 523-8.
18. Micallef IN, Apostolidis J, Rohatiner AZ, Wiggins C, Crawley CR, Foran JM etal. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J 2000; 1: 367-73.
19. Martino M, Callea I, Condemi A, Dattola A, Irrera G, Marcuccio D etal. Predictive factors that affect the mobilization of CD34(+) cells in healthy donors treated with recombinant granulocyte colony-stimulating factor (G-CSF). J Clin Apher 2006; 21: 169-75.
20. Lysak D, Koza V, Steinerova K, Jindra P, Vozobulova V, Schutzova M. Mobilization of peripheral blood stem cells in CLL patients after front-line fludarabine treatment. Ann Hematol 2005; 84: 456-61.
21. Nazha A, Cook R, Vogl DT, Mangan PA, Gardler M, Hummel K etal. Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen. Bone Marrow Transplant 2011; 46: 59-63.
22. Anwer F, Green M, Yeager AM. Effective primary mobilization of autologous peripheral blood stem cells with granulocyte colony-stimulating factor and plerixafor in lenalidomide-treated patients with multiple myeloma. Blood 2010; 116: abstract 2254.
23. Sinha S, Gastineau D, Micallef I, Hogan W, Ansell S, Buadi F etal. Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. Bone Marrow Transplant 2011; 46: 943-9.
24. Gazitt Y, Freytes CO, Callander N, Tsai TW, Alsina M, Anderson J etal. Successful PBSC mobilization with high-dose G-CSF for patients failing a first round of mobilization. J Hematother 1999; 8: 173-83.
25. Goterris R, Hernandez-Boluda JC, Teruel A, Gomez C, Lis MJ, Terol MJ etal. Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers. Bone Marrow Transplant 2005; 36: 847-53.
26. Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF etal. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008; 14: 1045-56.
27. Duarte R, Martin-Henao G, D'Addio A, Gayoso J, Shaw B, Russel N. Predictability of stem cell mobilization following G-CSF plus/minus plerixafor based on day 4 peripheral blood CD34+ levels: basis for a pre-emptive model of plerixafor use in patients with lymphoma and myeloma who mobilize poorly [abstract]. Bone Marrow Transplant 2010; 45: S323.
28. Alexander E. Cost effective use of Plerixafor for haemaphpoietic stem cells mobilization: development and validation of a decision making algorithm. Blood 2009; 114: abstract 3216.
29. Abhyankar S, Aljitawi OS, Ganguly N, McGuirk J, DeJarnette S, Merckel D. An algorithmic approach to evaluate the optimal use of Plerixafor (Mozobil(R)) for autologous hematopoietic peripheral blood stem cell (PBSC) collections based on peripheral circulating CD34 counts and day one collection yield in patients with multiple myeloma (MM) and lymphoma (NHL, HD) [abstract]. Biol Blood Marrow Transplant 2010; 16: S164-5.